Ascendis Pharma A/S News

Cantor Fitzgerald Corp.: Reiterates Ascendis Pharma (ASND.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $173.00.

Zhitong FinanceMay 3 23:00

Ascendis Pharma Analyst Ratings

BenzingaMay 3 22:58

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $173 Price Target

BenzingaMay 3 22:59

Ascendis Pharma Analyst Ratings

BenzingaApr 23 01:15

Ascendis Pharma Analyst Ratings

BenzingaApr 18 21:42

Ascendant Resources Analyst Ratings

BenzingaApr 17 18:24

Ascendis Pharma Analyst Ratings

BenzingaApr 2 22:46

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $173 Price Target

BenzingaApr 1 20:35

Ascendis Pharma Analyst Ratings

BenzingaApr 1 20:34

Ascendis Pharma Analyst Ratings

BenzingaMar 15 20:39

Ascendis Pharma Analyst Ratings

BenzingaFeb 8 21:25

Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $173

BenzingaFeb 6 22:49

Ascendis Pharma Analyst Ratings

BenzingaFeb 6 22:47

Wedbush Raises Price Target on Ascendis Pharma to $207 From $202, Maintains Outperform Rating

MT NewswiresJan 8 23:02

Ascendant Resources Analyst Ratings

BenzingaJan 8 19:17

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price Target

BenzingaDec 20, 2023 23:27

Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $202

BenzingaDec 20, 2023 21:58

Jefferies Initiates Coverage On Ascendis Pharma With Buy Rating, Announces Price Target of $150

BenzingaDec 20, 2023 19:37

Ascendis Pharma Analyst Ratings

BenzingaDec 20, 2023 19:36

Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $149

BenzingaDec 19, 2023 21:23